Treatment of Uterine Sarcoma in NTRK Fusion-Positive Gynecological Sarcoma
Clinical scenario
This protocol addresses uterine sarcoma arising in the context of an NTRK fusion-positive gynecological sarcoma — a rare subgroup of spindle cell tumors histologically resembling fibrosarcomas, defined by the presence of an underlying NTRK gene fusion.
Specific situation
The presence of an NTRK fusion places this tumor within a molecularly defined category. In locally advanced disease, the treatment approach is shaped by this molecular profile and the goal of enabling surgical resection with curative intent.
Treatment approach (partial overview)
For locally advanced disease, the protocol considers systemic treatment or radiotherapy as a means to facilitate subsequent resection. Among available systemic options, NTRK inhibitors are associated with the highest reported response rates in this setting.
Full regimen details, sequencing, and clinical decision criteria are available in the complete protocol.
References
- NTRK fusion-positive gynecological sarcomas are rare spindle cell tumors resembling fibrosarcomas.
- In patients with locally advanced disease, systemic treatment or radiotherapy can be considered to enable a subsequent resection with a curative intent. In this situation, the best response rates reported are with NTRK inhibitors (V, C).
DOI: 10.1136/ijgc-2024-005823
View source ↗